BACKGROUND: To describe the ocular changes noted in seven patients with type VI mucopolysaccharidosis (MPS VI) during 44 months of follow-up while on enzyme replacement therapy (ERT). METHODS: One male and six female patients with MPS VI were followed-up for a mean period of 44 months while undergoing enzyme replacement therapy (ERT) with recombinant arylsulfatase B (Naglazyme). They were examined annually for visual acuity, corneal clouding, intraocular pressure (IOP), optic nerve head and fundus morphology. Corneal clouding was documented by photography. We acknowledge that our methodology may not have been sensitive enough to detect extremely mild ocular changes, including minimal increases in corneal thickness or clouding. Nevertheless, this limitation has been considered in the interpretation of our findings. RESULTS: Ophthalmological findings remained stable in 5/7 patients. One patient experienced a modest improvement in visual acuity of more than 2 Snellen lines in one eye, while another patient suffered a deterioration in visual acuity of more than 2 Snellen lines in both eyes. Five out of seven patients showed optic nerve pathology: two of these exhibited optic nerve head swelling, while the other three showed variable degrees of optic nerve atrophy. All seven patients suffered from the typical corneal stromal opacities, however, to variable extents. CONCLUSION: Visual function and ocular findings did not deteriorate in six out of seven MPS VI patients during a mean follow-up period of 3 and a half years on ERT.
BACKGROUND: To describe the ocular changes noted in seven patients with type VI mucopolysaccharidosis (MPS VI) during 44 months of follow-up while on enzyme replacement therapy (ERT). METHODS: One male and six female patients with MPS VI were followed-up for a mean period of 44 months while undergoing enzyme replacement therapy (ERT) with recombinant arylsulfatase B (Naglazyme). They were examined annually for visual acuity, corneal clouding, intraocular pressure (IOP), optic nerve head and fundus morphology. Corneal clouding was documented by photography. We acknowledge that our methodology may not have been sensitive enough to detect extremely mild ocular changes, including minimal increases in corneal thickness or clouding. Nevertheless, this limitation has been considered in the interpretation of our findings. RESULTS: Ophthalmological findings remained stable in 5/7 patients. One patient experienced a modest improvement in visual acuity of more than 2 Snellen lines in one eye, while another patient suffered a deterioration in visual acuity of more than 2 Snellen lines in both eyes. Five out of seven patients showed optic nerve pathology: two of these exhibited optic nerve head swelling, while the other three showed variable degrees of optic nerve atrophy. All seven patients suffered from the typical corneal stromal opacities, however, to variable extents. CONCLUSION: Visual function and ocular findings did not deteriorate in six out of seven MPS VIpatients during a mean follow-up period of 3 and a half years on ERT.
Authors: C G Summers; R L Purple; W Krivit; R Pineda; G T Copland; N K Ramsay; J H Kersey; C B Whitley Journal: Ophthalmology Date: 1989-07 Impact factor: 12.079
Authors: Gabriella Cotugno; Patrizia Annunziata; Alessandra Tessitore; Thomas O'Malley; Anita Capalbo; Armida Faella; Rosa Bartolomeo; Patricia O'Donnell; Ping Wang; Fabio Russo; Meg M Sleeper; Van W Knox; Steven Fernandez; Leah Levanduski; John Hopwood; Elvira De Leonibus; Mark Haskins; Alberto Auricchio Journal: Mol Ther Date: 2010-11-30 Impact factor: 11.454
Authors: Bruno Duarte Gomes; Givago da Silva Souza; Gustavo Monteiro Viana; Isabel Cristina Neves de Souza; Patricia do Socorro Queiroz Feio; Ida Vanessa Doederlein Schwartz; Diane Ruschel Marinho; Manoel da Silva Filho; Roberto Giugliani; Luiz Carlos de Lima Silveira; Luiz Carlos Santana da Silva Journal: Case Rep Ophthalmol Date: 2012-03-26
Authors: Gustavo M Viana; Nathália O de Lima; Rosely Cavaleiro; Erik Alves; Isabel C N Souza; Raimunda Feio; Sandra Leistner-Segal; Ida Schwartz; Roberto Giugliani; Luiz C Santana da Silva Journal: Genet Mol Biol Date: 2011-07-01 Impact factor: 1.771